Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033644 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00033644 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00033644, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.
Interventions
- DRUG cisplatin
- DRUG dacarbazine
- DRUG doxorubicin hydrochloride
- BIOLOGICAL sargramostim
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033644
The ClinicalTrials.gov registry entry for NCT00033644 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00033644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033644 about?
NCT00033644 is a clinical study titled "Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from ...
What is the current status of trial NCT00033644?
This trial is currently terminated. It is a Phase 2 study. The study started on 2002-03.
What interventions are being tested in trial NCT00033644?
The interventions under investigation include: cisplatin (DRUG), dacarbazine (DRUG), doxorubicin hydrochloride (DRUG), sargramostim (BIOLOGICAL), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00033644?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.